Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Wang, Wen Ping ^a   Wang, Kang Ning ^a   Gao, Qiang ^a   Chen, Long Qi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adenocarcinoma of esophagogastric junction; Epidermal growth factor receptor; Gefitinib; Gene mutation; Single nucleotide polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLUTAMINE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURGERY; CANCER TISSUE; CODON; DNA EXTRACTION; DNA SEQUENCE; ESOPHAGEAL ADENOCARCINOMA; EXON; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MUTATION; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; CANCER STAGING; DRUG EFFECT; ESOPHAGUS TUMOR; GENETICS; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84855799452     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-14     Document Type: Article

References (22)

1. Wells A. EGF receptor. Int J Biochem Cell Biol 1999, 31(6):637-43. 10.1016/S1357-2725(99)00015-1, 10404636.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 2003, 284(1):31-53. 10.1016/S0014-4827(02)00098-8, 12648464.
3. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20(18 suppl):1S-13S.
4. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10(4):1212-8. 10.1158/1078-0432.CCR-03-0564, 14977817.
5. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(16):2149-58. 10.1001/jama.290.16.2149, 14570950.
6. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-500. 10.1126/science.1099314, 15118125.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-39. 10.1056/NEJMoa040938, 15118073.
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-92. 10.1056/NEJMoa044238, 15728811.
9. Dobelbower MC, Russo SM, Raisch KP, Seay LL, Clemons LK, Suter S, Posey J, Bonner JA. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006, 17(1):95-102. 10.1097/01.cad.0000185178.26862.4c, 16317296.
10. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006, 24(10):1612-9. 10.1200/JCO.2005.03.4900, 16575012.
11. He YT, Hou J, Chen ZF, Qiao CY, Song GH, Meng FS, Ji HX, Chen C. Analysis on epidemiology of gastric cardia carcinoma in high incidence area of esophageal carcinoma. Chin J Pub Heal 2006, 22(12):1434-35.
12. Chen WQ, Zhang SW, Chen ZF. An epidemiologic trend analysis on cardiac cancer in high incidence areas of esophageal cancer and gastric cancer in China. Bulletin Chin Cancer 2008, 17(12):998-1000.
13. Shao LF, Gao ZR, Wei GQ, Xu JL, Chen MY, Cheng JH. Surgical treatment of carcinoma of the esophagus and gastric cardia: 34-year investigation. Chin J Surgery 2001, 39(1):44-6.
14. Pühringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus 2007, 20(1):9-11. 10.1111/j.1442-2050.2007.00630.x, 17227303.
15. Mimori K, Nagahara H, Sudo T, Ishii H, Yamashita K, Barnard GF, Mori M. The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. J Surg Oncol 2006, 93(1):44-6. 10.1002/jso.20426, 16353180.
16. Ren JH, He WS, Yan GL, Jin M, Yang KY, Wu G. EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: A meta-analysis. Environ Mol Mutagen 2012, 53(1):78-82. 10.1002/em.20680, 22223435.
17. Huang YS, Yang JJ, Zhang XC, Yang XN, Huang YJ, Xu CR, Zhou Q, Wang Z, Su J, Wu YL. Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer. Chin Med J (Engl) 2011, 124(16):2457-60.
18. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011, 29(15):2066-70. 10.1200/JCO.2010.32.6181, 21482987.
19. Cui L, Pan XM, Ma CF, Shang-Guan J, Yu HB, Chen GX, Wang J. Association between epidermal growth factor polymorphism and esophageal squamous cell carcinoma susceptibility. Dig Dis Sci 2010, 55(1):40-5. 10.1007/s10620-008-0700-5, 19172394.
20. Goto Y, Ando T, Goto H, Hamajima N. No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(10):2454-6. 10.1158/1055-9965.EPI-05-0401, 16214932.
21. Choi JE, Park SH, Kim KM, Lee WK, Kam S, Cha SI, Kim CH, Kang YM, Kim YC, Han SB, Jung TH, Park JY. Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. BMC Cancer 2007, 7:198-206. 10.1186/1471-2407-7-198, 2151952, 17956604.
22. Kaneko K, Kumekawa Y, Makino R, Nozawa H, Hirayama Y, Kogo M, Konishi K, Katagiri A, Kubota Y, Muramoto T, Kushima M, Ohmori T, Oyama T, Kagawa N, Ohtsu A, Imawari M. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 2010, 15:65-72. 10.2741/3607, 20036807.